Similarities and differences between renal sympathetic denervation and carotid baroreceptor stimulation

Current Vascular Pharmacology

Volumn 12, Issue 1, 2014, Pages 63-68

  Grassi, Guido ^a,b   Seravalle, Gino ^a   Brambilla, Gianmaria ^a   Cesana, Francesca ^a   Giannattasio, Cristina ^a   Mancia, Giuseppe ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Carotid baroreceptor stimulation; End organ damage; Renal denervation; Resistant hypertension; Symapthetic activity

Indexed keywords

ADRENERGIC SYSTEM; ARTICLE; CAROTID SINUS PRESSORECEPTOR; CLINICAL TRIAL (TOPIC); ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HUMAN; IMPLANTATION; INVASIVE PROCEDURE; KIDNEY DENERVATION; MEAN ARTERIAL PRESSURE; PATHOPHYSIOLOGY; PRESSORECEPTOR REFLEX; RESISTANT HYPERTENSION;

ANIMALS; BLOOD PRESSURE; CATHETER ABLATION; ELECTRIC STIMULATION THERAPY; HUMANS; HYPERTENSION; KIDNEY; PRESSORECEPTORS; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84897468380     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990142     Document Type: Article

References (31)

1. Grassi G, Seravalle G, Fosca Quarti-Trevano, Dell'Oro R, Mancia G. Blood pressure control and antihypertensive treatment. Current Vascular Pharmacol 2012; 10: 506-511.
2. Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 124: 1046-58.
3. Krum H, Schlaich M, Sobotka P, Scheffers I, Kroon AA, deLeeuw PW. Novel procedure-and device-based strategies in the management of systemic hypertension. Eur Heart J 2011; 32: 537-44.
4. Esler M, Ferrier C, Lambert G, Eisenhofer G, Cox H, Jennings G. Biochemical evidence of sympathetic overactivity in human hypertension. Hypertension 1991; 17(suppl II): II29-35.
5. Stella A, Zanchetti A. Interactions between the sympathetic nervous system and the kidney: experimental observations. J Hypertens 1985; 3: S19-25.
6. DiBona GF, Esler MD. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010; 298: R245-53.
7. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-81.
8. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-9.
9. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-7.
10. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-4.
11. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940-6.
12. Schlaich MP, Straznicky N, Grima M, et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens 2011; 29: 991-6.
13. Lembo G, Grassi G. A lesson from polycystic ovarian syndrome: untangling the role of renal sympathetic nervous system on hypertension and insulin resistance. J Hypertens 2011; 29: 836-7.
14. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-65.
15. Krum H, Barman N, Schlaich M, et al. Long-term follow-up of catheter-based renal denervation for resistant hypertension confirms durable reduction of blood pressure values. J Am Coll Cardiol 2012; 59: E1704.
16. Lohmeier TE, Loheimer JR, Haque A, et al. Baroreflexes prevent neurally induced sodium retention in angiotensin hypertension. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1437-R48.
17. Lohmeier TE, Irwin E, Rossing M, et al. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension. 2004; 4: 306-11.
18. Barrett CJ, Guild S, Ramchandra J, et al. Baroreceptor denervation prevents sympathoinhibition during angiotensin II-induced hypertension. Hypertension. 2005; 46: 1-5.
19. Lohmeier TE, Dwyer TM, Irwin ED, et al. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension. 2007; 49: 1307-14.
20. Bisognano JD, Kaufman CL, Bach DS, Lovett EG, de Leeuw P, DEBuT-HT and Rheos Feasibility Trial Investigators. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J Am Coll Cardiol 2011; 57: 1787-8.
21. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in paients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos pivotal trial. J Am Coll Cardiol 2011; 58: 765-73.
22. Bakris GL, Nadim Mk, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy providesdurable benfit in patient with resistant hypertension: results of the long-term followup in the Rheos Pivotal trail. J Am Soc Hypertens 2012; 6: 152-8.
23. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 2009; 54: 690-7.
24. Grassi G. Sympathetic neural activity in hypertension and related diseases. Am J Hypertens 2010; 23: 1052-8.
25. Seravalle G, Volpe M, Ganz F, et al. Neuroadrenergic profile in patients with resistant hypertension. J Hypertens 2011; 29: e141.
26. Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901-9.
27. Zuern CS, Rizas KD, Eick C, et al. Front Physiol. Effects of renal sympathetic denervation on 24-hour blood pressure variability. Front Physiol 2012; 3: 134.
28. Lohmeier T, Niescu R. Chronic lowering of blood pressure by carotid baroreflex activation. Hypertens 2011; 57: 880-6
29. Schmieder RE, Redon J, Grassi G, et al. ESH Position Paper: renal denervation-an interventional therapy of resistant hypertension. J Hypertens 2012; 30: 837-41.
30. Laurent S, Schlaich M, Esler MD. New drugs, procedures and devices for hypertension. Lancet 2012; 380: 591-600.
31. Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the Symplicity HTN-3 Trial. Clin Cardiol 2012; 35.528-535.